Rotavirus vaccines: A story of success

Clinical Microbiology and Infection

Volumn 21, Issue 8, 2015, Pages 735-743

  Kollaritsch, H ^a   Kundi, M ^a   Giaquinto, C ^b   Paulke Korinek, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Circulating genotypes; Cost effectiveness; Field effectiveness; Intussusception; Rotavirus vaccination

Indexed keywords

LIVE VACCINE; ROTAVIRUS VACCINE;

COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; GENOTYPE; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; INTUSSUSCEPTION; MASS IMMUNIZATION; PRIORITY JOURNAL; REVIEW; VACCINATION; CHEMICALLY INDUCED; HEALTH; IMMUNOLOGY; INCIDENCE; PREVENTIVE HEALTH SERVICE; ROTAVIRUS INFECTIONS;

BOVINAE; ROTAVIRUS;

COST-BENEFIT ANALYSIS; GLOBAL HEALTH; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INTUSSUSCEPTION; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES;

EID: 84937438591     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.01.027     Document Type: Review

References (75)

1. World Health Organization Rotavirus vaccines WHO position paper January 2013. WER 2013, 88:49-64.
2. World Health Organization Safety profile of a novel live attenuated rotavirus vaccine. WER 2014, 89:326-327.
3. World Health Organization Rotavirus vaccines: an update. WER 2009, 84:533-540.
4. Tate J.E., Patel M.M., Steele A.D., Gentsch J.R., Payne D.C., Cortese M.M., et al. Global impact of rotavirus vaccines. Exp Rev Vac 2010, 9:395-407.
5. John J., Sarkar R., Muliyil J., Bhandari N., Bhan M.K., Kang G. Rotavirus gastroenteritis in India, 2011-2013: revised estimates of disease burden and potential impact of vaccines. Vaccine 2014, 32(Suppl. 1):A5-A9.
6. Richardson V., Parashar U., Patel M. Childhood diarrhea deaths after rotavirus vaccination in Mexico. N Engl J Med 2011, 365:772-773.
7. Richardson V., Hernandez-Pichardo J., Quintanar-Solares M., Esparza-Aguilar M., Johnson B., Gomez-Altamirano C.M., et al. Effect of rotavirus vaccination on death from childhood diarrhea in Mexico. N Engl J Med 2010, 362:299-305.
8. Tate J.E., Parashar U.D. Rotavirus vaccines in routine use. Clin Infect Dis 2014, 59:1291-1301.
9. Rota Council [Internet]. National and Regional Rotavirus Vaccine Introductions. Available at:[last accessed 15.12.14]. http://rotacouncil.org/national-and-regional-rotavirus-introductions/.
10. Parez N., Giaquinto C., Du Roure C., Martinon-Torres F., Spoulou V., Van Damme P., et al. Rotavirus vaccination in Europe: drivers and barriers. Lancet Infect Dis 2014, 14:416-425.
11. Bundesamt für Gesundheit und Eidgenössische Kommission für Impffragen. Schweizerischer Impfplan 2014. Available at:[last accessed 15.12.14]. http://www.infovac.ch/de/.
12. Giaquinto C., Dominiak-Felden G., Van Damme P., Myint T.T., Maldonado Y.A., Spoulou V., et al. Summary of effectiveness and impact of rotavirus vaccination with the oral pentavalent rotavirus vaccine: a systematic review of the experience in industrialized countries. Hum Vaccin 2011, 7:734-748.
13. Lopman B.A., Curns A.T., Yen C., Parashar U.D. Infant Rotavirus Vaccination may provide indirect protection to older children and adults in the United States. J Infect Dis 2011, 204:980-986.
14. Paulke-Korinek M., Kundi M., Rendi-Wagner P., de Martin A., Eder G., Schmidle-Loss B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 2011, 29:2791-2796.
15. Field E.J., Vally H., Grimwood K., Lambert S.B. Pentavalent rotavirus vaccine and prevention of gastroenteritis hospitalizations in Australia. Pediatrics 2010, 126(3):e506-e512.
16. Payne D.C., Staat M.A., Edwards K.M., Szilagyi P.G., Weinberg G.A., Hall C.B., et al. Direct and indirect effects of rotavirus vaccination upon childhood hospitalizations in 3 US counties, 2006-2009. Clin Infect Dis 2011, 53:245-253. New Vaccine Surveillance Network (NVSN).
17. Patel M.M., López-Collada V.R., Bulhões M.M., De Oliveira L.H., Bautista Márquez A., Flannery B., et al. Intussusception risk and health benefits of rotavirus vaccination in Mexico and Brazil. N Engl J Med 2011, 364:2283-2292.
18. Clark A., Jit M., Andrews N., Atchison C., Edmunds W.J., Sanderson C. Evaluating the potential risks and benefits of infant rotavirus vaccination in England. Vaccine 2014, 32:3604-3610.
19. Soriano-Gabarró M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
20. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Kronik R., Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010, 29:319-323.
21. Paulke-Korinek M., Kollaritsch H., Aberle S.W., Zwazl I., Schmidle-Loss B., Vécsei A., et al. Sustained low hospitalization rates after four years of rotavirus mass vaccination in Austria. Vaccine 2013, 31:2686-2691.
22. Uhlig U., Kostev K., Schuster V., Koletzko S., Uhlig H.H. Impact of rotavirus vaccination in Germany: rotavirus surveillance, hospitalization, side effects and comparison of vaccines. Pediatr Infect Dis J 2014, 33:e299-304.
23. Braeckman T., Van Herck K., Meyer N., Pirçon J.Y., Soriano-Gabarró M., Heylen E., et al. Effectiveness of rotavirus vaccination in prevention of hospital admissions for rotavirus gastroenteritis among young children in Belgium: case-control study. BMJ 2012, 345:e4752. RotaBel Study Group.
24. Public Health England National rotavirus immunization programme: preliminary data for England, October 2013 to September 2014. Health Protection Report 2014, 8(41). Available at:, [last accessed 15.12.14]. https://www.gov.uk/government/publications/rotavirus-immunisation-programme-vaccine-coverage-estimates.
25. Hemming M., Räsänen S., Huhti L., Paloniemi M., Salminen M., Vesikari T. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur J Pediatr 2013, 172:739-746.
26. Standaert B., Gomez J.A., Raes M., Debrus S., Velázquez F.R., Postma M.J. Impact of rotavirus vaccination on hospitalisations in Belgium: comparing model predictions with observed data. PLoS One 2013, 8:e53864.
27. ®, into the national immunization program of Australia. Pediatr Inf Dis J 2011, 30:48-53.
28. Curns A., Steiner C., Barrett M., Hunter K., Wilson E., Parashar U. Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US States. J Infect Dis 2010, 201:1617-1624.
29. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33. Rotavirus Efficacy and Safety Trial (REST) Study Team.
30. Vesikari T., Karvonen A., Prymula R., Schuster V., Tejedor J.C., Cohen R., et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study. Lancet 2007, 370:1757-1763.
31. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22. Human Rotavirus Vaccine Study Group.
32. Payne D.C., Boom J.A., Staat M.A., Edwards K.M., Szilagyi P.G., Klein E.J., et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis 2013, 57:13-20.
33. ®, in Finnish infants up to 3 years of age: the Finnish Extension Study. Eur J Pediatr 2010, 169:1379-1386.
34. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: a randomized clinical trial in an Asian population. Vaccine 2012, 30:4552-4557.
35. Jit M., Bilcke J., Mangen M.J., Salo H., Melliez H., Edmunds W.J., et al. The cost-effectiveness of rotavirus vaccination: comparative analyses for five European countries and transferability in Europe. Vaccine 2009, 27:6121-6128.
36. Tilson L., Jit M., Schmitz S., Walsh C., Garvey P., McKeown P., et al. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland. Vaccine 2011, 29:7463-7473.
37. Aidelsburger P., Grabein K., Böhm K., Dietl M., Wasem J., Koch J., et al. Cost-Effectiveness of childhood rotavirus vaccination in Germany. Vaccine 2014, 32:1964-1974.
38. Atkins K.E., Shim E., Pitzer V.E., Galvani A.P. Impact of rotavirus vaccination on epidemiological dynamics in England and Wales. Vaccine 2012, 30:552-564.
39. Chodick G., Waisbourd-Zinman O., Shalev V., Kokia E., Rabinovich M., Ashkenazi S. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel. Eur J Public Health 2009, 19:254-259.
40. ®) and intussusception April 22, 2011, Available at:, [last accessed 03.11.14]. http://www.cdc.gov/vaccines/vpd-vac/rotavirus/vac-rotashield-historical.htm.
41. Murphy T.V., Gargiullo P.M., Massoudi M.S., Nelson D.B., Jumaan A.O., Okoro C.A., et al. Intussusception among infants given an oral rotavirus vaccine. N Engl J Med 2001, 344(8):564-572. Rotavirus Intussusception Investigation Team.
42. Jiang J., Jiang B., Parashar U., Nguyen T., Bines J., Patel M.M. Childhood intussusception: a literature review. PLoS One 2013, 8:e68482.
43. Sáez-Llorens X., Velázquez F.R., Lopez P., Espinoza F., Linhares A.C., Abate H., et al. A multi-country study of intussusception in children under 2 years of age in Latin America: analysis of prospective surveillance data. BMC Gastroenterol 2013, 13:95.
44. Eng P.M., Mast T.C., Loughlin J., Clifford C.R., Wong J., Seeger J.D. Incidence of intussusception among infants in a large commercially insured population in the United States. Pediatr Infect Dis J 2012, 31:287-291.
45. Soares-Weiser K., Maclehose H., Bergman H., Ben-Aharon I., Nagpal S., Goldberg E., et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012, 11:CD008521.
46. Rha B., Tate J.E., Weintraub E., Haber P., Yen C., Patel M., et al. Intussusception following rotavirus vaccination: an updated review of the available evidence. Expert Rev Vaccines 2014, 13:1339-1348.
47. Desai R., Cortese M.M., Meltzer M.I., Shankar M., Tate J.E., Yen C., et al. Potential intussusception risk versus benefits of rotavirus vaccination in the United States. Pediatr Infect Dis J 2013, 32:1-7.
48. Carlin J.B., Macartney K.K., Lee K.J., Quinn H.E., Buttery J., Lopert R., et al. Intussusception risk and disease prevention associated with rotavirus vaccines in Australia's National Immunization Program. Clin Infect Dis 2013, 57:1427-1434.
49. Loughlin J., Mast T.C., Doherty M.C., Wang F.T., Wong J., Seeger J.D. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. Pediatr Infect Dis J 2012, 31:292-296.
50. Jain S., Vashistt J., Changotra H. Rotaviruses: is their surveillance needed?. Vaccine 2014, 32:3367-3378.
51. Matthijnssens J., Ciarlet M., McDonald S.M., Attoui H., Bányai K., Brister J.R., et al. Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG). Arch Virol 2011, 156:1397-1413.
52. Leshem E., Lopman B., Glass R., Gentsch J., Bányai K., Parashar U., et al. Distribution of rotavirus strains and strain-specific effectiveness of the rotavirus vaccine after its introduction: a systematic review and meta-analysis. Lancet Infect Dis 2014, 14:847-856.
53. Matthijnssens J., Zeller M., Heylen E., De Coster S., Vercauteren J., Braeckman T., et al. Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses. Clin Microbiol Infect 2014, 20:O702-O710. RotaBel study group.
54. Payne D.C., Szilagyi P.G., Staat M.A., Edwards K.M., Gentsch J.R., Weinberg G.A., et al. Secular variation in United States rotavirus disease rates and serotypes: implications for assessing the rotavirus vaccination program. Pediatr Infect Dis J 2009, 28:948-953.
55. Van Damme P., Giaquinto C., Huet F., Gothefors L., Maxwell M., Van der Wielen M. Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 2007, 195(Suppl. 1):S4-S16. REVEAL Study Group.
56. Zeller M., Rahman M., Heylen E., De Coster S., De Vos S., Arijs I., et al. Rotavirus incidence and genotype distribution before and after national rotavirus vaccine introduction in Belgium. Vaccine 2010, 28:7507-7513.
57. Aberle, S. Rotavirus: Überwachung zirkulierender Serotypen. Virusepidemiologische Information 2011; 20. Available at: [last accessed 15.12.14]. http://www.virologie.meduniwien.ac.at/home/upload/vei/2011/2011.pdf.
58. Adlhoch C., Hoehne M., Littmann M., Marques A.M., Lerche A., Dehnert M., et al. Rotavirus vaccine effectiveness and case-control study on risk factors for breakthrough infections in Germany, 2010-2011. Pediatr Infect Dis J 2013, 32:e82-e89.
59. Dulgheroff A.C.B., Figueiredo E.F., Moreira K.C., Moura L.M., Gouvêa V.S., et al. Distribution of rotavirus genotypes after vaccine introduction in the Triangulo Mineiro region of Brazil: 4-Year follow-up study. J Clin Virol 2012, 55:67--71.
60. ® vaccine in Rio de Janeiro, Brazil. Water Res 2011, 45:5755-5763.
61. Cortese M.M., Immergluck L.C., Held M., Jain S., Chan T., Grizas A.P., et al. Effectiveness of monovalent and pentavalent rotavirus vaccine. Pediatrics 2013, 132:e25-33.
62. Hull J.J., Teel E.N., Kerin T.K., Freeman M.M., Esona M.D., Gentsch J.R. National Rotavirus Strain Surveillance System. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011, 30(Suppl. 1):S42-S47. National Rotavirus Strain Surveillance System.
63. Dóró R., László B., Martella V., Leshem E., Gentsch J., Parashar U., et al. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: Is there evidence of strain selection from vaccine pressure?. Infect Genet Evol 2014, 28:446-461.
64. Castilla J., Beristain X., Martínez-Artola V., Navascués A., García Cenoz M., Alvarez N., et al. Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain. Vaccine 2012, 30:539-543.
65. Groome M.J., Page N., Cortese M.M., Moyes J., Zar H.J., Kapongo C.N., et al. Effectiveness of monovalent human rotavirus vaccine against admission to hospital for acute rotavirus diarrhoea in South African children: a case-control study. Lancet Infect Dis 2014, 14:1096-1104.
66. Staat M.A., Payne D.C., Donauer S., Weinberg G.A., Edwards K.M., Szilagyi P.G., et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics 2011, 128(2):e267-e275. New Vaccine Surveillance Network (NVSN).
67. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Hull J.J., Gentsch J.R., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125:e199-e207.
68. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Quaye O., Mijatovic-Rustempasic S., et al. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital. Pediatr Infect Dis J 2010, 29:1133-1135.
69. Muhsen K., Shulman L., Kasem E., Rubinstein U., Shachter J., Kremer A., et al. Effectiveness of rotavirus vaccines for prevention of rotavirus gastroenteritis-associated hospitalizations in Israel: a case-control study. Hum Vaccin 2010, 6:450-454.
70. Velázquez F.R., Colindres R.E., Grajales C., Hernández M.T., Mercadillo M.G., Torres F.J., et al. Postmarketing surveillance of intussusception following mass introduction of the attenuated human rotavirus vaccine in Mexico. Pediatr Infect Dis J 2012, 31:736-744.
71. Buttery J.P., Danchin M.H., Lee K.J., Carlin J.B., McIntyre P.B., Elliott E.J., et al. Intussusception following rotavirus vaccine administration: post-marketing surveillance in the National Immunization Program in Australia. Vaccine 2011, 29:3061-3066. PAEDS/APSU Study Group.
72. Shui I.M., Baggs J., Patel M., Parashar U.D., Rett M., Belongia E.A., et al. Risk of intussusception following administration of a pentavalent rotavirus vaccine in US infants. JAMA 2012, 307:598-604.
73. Haber P., Patel M., Pan Y., Baggs J., Haber M., Museru O., et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics 2013, 131:1042-1049.
74. Weintraub E.S., Baggs J., Duffy J., Vellozzi C., Belongia E.A., Irving S., et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014, 370:513-519.
75. Yih W.K., Lieu T.A., Kulldorff M., Martin D., McMahill-Walraven C.N., Platt R., et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014, 370:503-512.